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Abstract
Background: Many methods have been developed to test the enrichment of genes related to
certain phenotypes or cell states in gene sets. These approaches usually combine gene expression
data with functionally related gene sets as defined in databases such as GeneOntology (GO),
KEGG, or BioCarta. The results based on gene set analysis are generally more biologically
interpretable, accurate and robust than the results based on individual gene analysis. However,
while most available methods for gene set enrichment analysis test the enrichment of the entire
gene set, it is more likely that only a subset of the genes in the gene set may be related to the
phenotypes of interest.
Results:  In this paper, we develop a novel method, termed Sub-GSE, which measures the
enrichment of a predefined gene set, or pathway, by testing its subsets. The application of Sub-GSE
to two simulated and two real datasets shows Sub-GSE to be more sensitive than previous
methods, such as GSEA, GSA, and SigPath, in detecting gene sets assiated with a phenotype of
interest. This is particularly true for cases in which only a fraction of the genes in the gene set are
associated with the phenotypes. Furthermore, the application of Sub-GSE to two real data sets
demonstrates that it can detect more biologically meaningful gene sets than GSEA.
Conclusion: We developed a new method to measure the gene set enrichment. Applications to
two simulated datasets and two real datasets show that this method is sensitive to the associations
between gene sets and phenotype. The program Sub-GSE can be downloaded from http://www-
rcf.usc.edu/~fsun.
Background
Genome-wide gene expression profiling using microarray
technologies has been ubiquitously used in biological
research. An important problem is to identify gene sets
that are significantly changed under a certain treatment
(for example, two different cell lines or tissues or the same
cell line under different conditions). A gene set is basically
a group of genes with related functions, e.g., genes in a
biological process or in the same complex. There are a
variety of ways by which genes, and, ultimately, gene sets
may be defined. For example, gene sets can be defined
according to the information provided by several data-
bases, such as GeneOntology [1], KEGG [2], Biocarta
http://www.biocarta.com, and Pfam [3]. Gene sets may
also be defined by cytogenetic bands, by region of
genomic sequence or by establishing the functional rela-
tionships among them. Importantly, by using a gene set-
based approach, a high power can potentially be achieved
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for detecting differentially expressed gene sets by integrat-
ing expression changes of genes inside the same gene set,
even when the expression changes of individual genes are
modest.
Moreover, because the gene sets have already been anno-
tated by their common functions in the databases, the
biological interpretation for a given list of significant gene
sets will also be clear. At least one study [4] showed that
using such gene set-based approaches did increase the
congruence of the identified gene sets between different
data sets addressing the same biological problem. To
detect differentially expressed gene sets, several methods
have been proposed, which can be roughly categorized
into three groups.
The first group identifies a list of significant differentially
expressed genes (DEGs) using individual gene analysis
methods, and then examines the enrichment of gene sets
within this gene list using different statistical tests, such as
the binomial test, Fisher's exact test, or the hypergeomet-
ric test [5-11]. Khatri and Draghici [12] compared four-
teen different methods within this group. Each of these
methods is easy to implement, but flawed by 1) sensitivity
to the cutoff value for defining the list of significant DEGs,
2) non-consideration of the relative position of genes
inside the significant DEG list, and 3) assumption of inde-
pendence between the genes, which may make the result-
ing p-value misleading.
The second group of methods does not depend on the
predefined DEG list. Instead, these methods calculate a
gene-specific statistic, known as the "local" statistic, which
measures the strength of association between the gene
expression and the phenotype for each gene. A "global"
statistic for a gene set is then constructed as a function of
the local statistic for each gene in it. The significance of the
global statistic is assessed by permutation test, and differ-
ent methods arrive at this assessment in different ways
[13-21]. In contrast to calculating a gene-specific statistic,
the third group of methods directly combines the expres-
sion levels of all genes in the gene sets and they are repre-
sented as gene set-specific features. These features are then
compared between the treatment and the control groups
to identify significantly affected gene sets [22-27]. Some
methods also integrated the interaction information
between genes in the gene sets [28-31].
The available methods generally tested the association of
all the genes in a gene set with the phenotype. In reality,
however, it is more likely that only genes in a subset of the
gene set of interest are associated with the phenotype.
Three possible factors may explain this. First, since the
function annotation defined in the available databases,
such as GO, KEGG, and Biocarta, are incomplete, or even
erroneous, some of the genes in a gene set of interest may
not truly belong to the set. Second, the gene sets are some-
times defined according to the genomic regions of the
genes. Thus, the expression of the genes in the same set
may not coordinate with each other. For example,
although a group of gene sets has been defined by the
cytogenetic bands on human chromosomes [14], the
expression of genes on the same cytogenetic bands do not
necessarily correlate with each other. The result is that
only a subset of genes in a given cytogenetic band will
then be correlated with a phenotype. Third, even if all the
genes in the gene set have the same function, or belong to
the same complex, it is possible that only genes in one
branch of the pathway are associated with the phenotype.
The cumulative effect of these considerations strongly sug-
gests that the currently available methods for gene set
enrichment analysis may not be powerful enough to
detect the association of a given gene set with a pheno-
type, particularly in the case where only a subset of the
genes is associated with the phenotype.
In this paper, therefore, we extend a set-association strat-
egy for genetic polymorphism association studies devel-
oped by [32] to a set-enrichment analysis. In so doing, we
want to test the null hypothesis that no subsets of genes in
the gene set are associated with the phenotype. We refer to
the resulting method as Gene Set Enrichment by testing
Subset association, or Sub-GSE. Using two simulated data
sets, we first show that Sub-GSE has higher sensitivity in
identifying gene sets associated with a phenotype com-
pared to GSEA, SigPath, and GSA, when only a fraction of
the genes are associated with the phenotype. Next, we
apply Sub-GSE to two real data sets. One involves gene
expression data related to gender and the other identified
functional gene sets related to p53 mutation status. For
the first dataset, Sub-GSE identified cytogenetic bands
Xp22 as significantly associated with gender, while GSEA
failed to detect this association. For the second dataset,
Sub-GSE identified several novel functional gene sets,
including DNA damage genes, cell cycle checkpoints
genes and programmed cell death genes that are associ-
ated with p53 mutation status and that were also not
detected by GSEA. Overall, this method provides a com-
plementary approach for identifying gene sets associated
with a phenotype, especially when only a subset of genes
in a gene set is associated with the phenotype.
Results and discussion
In this section, we first give a brief overview of our
method. Second, we apply Sub-GSE, GSEA, SigPathway,
and GSA to two simulated data sets and compare their
performance. Third, we apply Sub-GSE to two real data-
sets: one related to gender and the other related to p53
mutation status. We also show some new biological find-
ings related to the two real data sets using Sub-GSE.BMC Bioinformatics 2008, 9:362 http://www.biomedcentral.com/1471-2105/9/362
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Outline of the method
To assess the enrichment of a given gene set, we construct
a statistical hypothesis testing model. The null hypothesis
is that no subsets of genes in the given gene set are associ-
ated with the phenotype.
Defining the "strict subsets"
Given the fact that the number of all subsets of a gene set
increases exponentially with the number of genes in the
gene set, it is impractical and less powerful to test every
subset of the gene set. Therefore, we define the "strict sub-
sets" to only those subsets that are more likely to be
related with the phenotype. To define the "strict subsets"
of a gene set, we first calculate the association strength
between the gene expression and the phenotype for each
gene in the gene set. Depending on the measurement lev-
els of the phenotypic data, we calculate the absolute t-sta-
tistics for comparing the mean gene expression levels for
binary phenotypic data, Kruskal-Wallis statistics for com-
paring the mean expression levels of different groups for
discrete phenotypic data, and the absolute Pearson corre-
lation coefficient between the gene expression levels and
the phenotype for continuous data. All genes are sorted in
decreasing order of the association strength measures. The
"strict subsets" are defined to include genes up to each
position from the top to the bottom in the ranked gene
list, which are most strongly associated with the pheno-
type. That is to say, for each position in the ranked gene
list, we define a strict subset that includes all the genes that
are ranked higher than this position. Thus, if there are n
genes in the gene set, there will be n "strict subsets" among
which the i-th subset contains the top i  genes in the
ranked gene list according to the association strengths. In
this way, the number of subsets to be tested increases lin-
early with the number of genes in the gene set. Since the
strict subsets includes the genes that are most associated
with the phenotype, we expect them to be more probable
to be related with the phenotype. The strict subsets are
defined to be contiguous to include as many as possible
subsets that are expected to be more likely related with the
phenotype. However, the method we propose here cannot
detect the gene sets in which individual genes are not asso-
ciated with the phenotype but they can interact with each
other to affect the phenotype. To overcome the problem
that the "strict subsets" contain too few genes, we add a
tuning parameter to control the sizes of the "strict sub-
sets". Throughout the paper, we set this tuning parameter
to be 5 which means the "strict subsets" are required to
contain at least 5 genes. The cutoff for the set size of the
strict subsets is set to be 5 so that the method is not too
sensitive to detect gene set which has only one gene
strongly correlated with the phenotype. There are other
ways of deciding the cutoff of the set size as discussed in
the Conclusions section.
Testing Statistic
The hypothesis testing statistic is calculated in three steps.
First, for each "strict subset", we calculate the average asso-
ciation strength across all member genes, which is also
called the local set association statistic T. Second, the sta-
tistical significance (raw p-value) of the local set associa-
tion statistic T  for each "strict subset" is calculated by
permuting the phenotypes of the individuals. Finally, the
minimum raw p-value among all the "strict subsets" is
evaluated and taken as the hypothesis testing statistic. If
there is any strict subset related with the phenotype, the
minimum p-value will be significantly small.
Significance Assessment
To assess the significance of the minimum p value, nested
permutation is needed since we do not know the distribu-
tion of T under the null hypothesis However, nested per-
mutation is computation intensive. Fortunately, previous
work [33] has shown that a single set of permutation is
sufficient to accomplish the significance assessment. For
the permutation, we decide to permute the phenotypic
data and keep the gene expression data intact due to the
criticism on gene-based permutation which assumes the
independence between genes [16].
The phenotypic data is permuted for N times. After each
permutation, the "strict subsets" are re-defined according
to the newly calculated association strengths using the
permuted phenotypic data. The strict subsets are defined
in the same way as we did with the observed data includ-
ing the threshold of set size.
The only difference is that the phenotypic data is changed.
By comparing the set association statistic T  from the
observed data and those from the permuted data, raw p
values can be calculated for all the observed "strict sub-
sets" and thus the observed Pmin is obtained. To estimate
the distribution of Pmin under the null hypothesis, as clas-
sic permutation does, we replace the observed phenotypic
data with every permuted phenotypic data and compare
the set association statistic with those from all the other N
- 1 permutations. In other words, we repeat exactly the
same procedure to obtain the minimum raw p values for
every permuted data. Finally, the significance of the gene
set will be the percentage of permutations that result in
minimum raw p values smaller than the observed Pmin. If
there are more than one given gene set, multiple testing
correction can be done using any multiple testing correc-
tion method. In this paper, we use the QVALUE R package
[34] to calculate the q-values for the two biological data
sets so that the results by Sub-GSE are comparable with
other gene set enrichment analysis methods.BMC Bioinformatics 2008, 9:362 http://www.biomedcentral.com/1471-2105/9/362
Page 4 of 15
(page number not for citation purposes)
Simulation Studies
We first elucidate that the p-values do not depend on the
size of the gene set and the p-value has a uniform distribu-
tion in [0,1] under the null hypothesis. To achieve these
objectives, we simulate a data set where all the gene sets
have different set sizes and no gene sets are related to the
phenotype. The simulation is implemented in the follow-
ing steps:
1. Generate 100 gene sets whose sizes are 5,6,7,8,...,104.
The total number of genes is 5450;
2. The gene expression levels in 100 samples for each gene
are generated from a standard normal distribution. Differ-
ent genes are independent of each other. Different sam-
ples are also independent of each other;
3. Generate the phenotypic data from another independ-
ent standard normal distribution in 100 samples;
4. Repeat steps 1–3 for 100 times;
In total, the simulation generates 100 data sets that have
gene expression data and a corresponding phenotypic
data. We apply Sub-GSE to the 100 data sets separately.
First, since the gene sets have different sizes, we plot the
average p-values of all the gene sets across the 100 differ-
ent data sets against their set sizes to see whether the gene
set size affects the significance level. Figure 1 shows that
the set size does not affect the p-values.
Second, the phenotypic data is independent of the expres-
sion levels of all the genes. Therefore, Sub-GSE should not
detect any significant gene sets. In Figure 2, the histogram
of all the p-values of the 100 gene sets from the 100 data
sets is shown. The histogram illustrates that the p-values
from the Sub-GSE have a uniform distribution for gene
sets that are not related to the phenotype, which is consist-
ent with the theoretical uniform distribution under the
null hypothesis.
Simulation 1
We first evaluate the performance of Sub-GSE using simu-
lated data in which gene expression profiles with different
correlations within the gene set are generated. The expres-
sion profiles for 1000 genes in 100 samples are simulated.
The genes are divided into 50 non-overlapping gene sets
with 20 genes in each. The gene expression profiles for the
100 samples represent 100 independent vectors of ran-
dom variables generated from a multivariate normal dis-
tribution. The multivariate normal distribution has 1000
dimensions corresponding to the 1000 genes. The mean is
a vector of 1000 zeroes, and the variance of the expression
levels of each gene is 1. To simulate the dependence
between genes, we randomly select a certain percentage of
correlated genes (PCG) = (0%, 10%, , 90%) in each gene
set and let the correlation coefficient between any two of
them be ρ = 0, 0.1, 0.2, , 0.9. The remaining genes are
independent of each other and those that are chosen. We
use this simulation strategy based on the following con-
siderations. The chosen genes in the gene set correspond
to those in the same complex or pathway; thus, their
expression profiles are correlated. Also, since the remain-
ing genes represent those not belonging to the group, they
are more likely to be independent of the chosen genes and
each other.
If a given gene is among those that are chosen, we use its
expression levels as the phenotype. The rationale of this
step is to determine if our Sub-GSE method can identify
the gene set to which this particular gene belongs. We
repeat this process for all the chosen genes. Thus, we have
a total of 1000 × PCG different phenotypic data. To avoid
the problem where a gene has exactly the same expression
profile as the phenotype, we eliminate the gene's expres-
sion profile from the expression data if it is used as the
phenotype.
We use the following approach to study the robustness of
Sub-GSE. For each given correlation coefficient and PCG,
we randomly choose one of the simulated phenotypic
data and the corresponding gene expression data. Sub-
GSE is applied to the chosen data set for 100 times. The
Effect of set size on the p-values Figure 1
Effect of set size on the p-values. The average p-values of 
the 100 gene sets across the 100 different data sets are plot-
ted against their corresponding set sizes.
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standard deviations of the p-values across the 100 differ-
ent runs are plotted against the average p-values for all the
gene sets in Figure 3. The figure shows that the standard
deviation of the p-value for the same gene set is smaller
than 0.006 and even smaller when the p-value is close to
either 1 or 0. The closer the p-value is to 0 or 1, the smaller
the standard deviation is. The maximum standard devia-
tion is achieved when the average p-value is around 0.5.
For each given pair of percentage of correlated genes
(PCG) and correlation coefficient, we apply all four meth-
ods, Sub-GSE, GSEA, GSA, and SigPath, to the corre-
sponding data. All the gene sets are ranked in an
increasing order of their q-values so more significant gene
sets have smaller rank. The rank of the gene set, some of
whose member genes are correlated with the phenotypic
data, is extracted to evaluate the performance of the meth-
ods. Figure 4 shows the average rank of the gene set related
to the phenotype for different combinations of PCG and
correlation coefficient.
First, as seen in the left panel in Figure 4, for small PCG =
10%, 20% and 30%, the average rank of the gene set
related to the phenotype based on Sub-GSE is always the
lowest, irrespective of the coefficient value. On the other
hand, for large PCG, the performance of Sub-GSE is simi-
lar or slightly worse than GSEA and GSA for small correla-
tion. The right panel in Figure 4 confirms this because the
average rank of the gene set related to the phenotype
based on Sub-GSE decreases much faster than those for
the other methods when PCG is small. The results of Fig-
ure 4 can be explained as follows. When PCG is low, only
a small fraction of the genes in the target gene set are cor-
related with the phenotype. GSEA, GSA, and SigPath can-
not distinguish the target gene set from the other gene sets
since these methods consider all the genes in the gene set
of interest in their statistics. In contrast, Sub-GSE incre-
mentally tests each strict set and chooses the smallest p-
value across all the strict sets as a test statistic, thus making
the test more powerful.
Second, across different combinations of PCG and corre-
lation coefficient, we find that GSA and GSEA achieve
similar results. Both GSA and GSEA use t-statistics to
obtain the ranking list of genes. For applications in this
article, the only diference between them is that GSA
restandardizes the statistics before the permutation to
reduce the effect of correlation between genes. However,
in both panels of Figure 4, the average ranks of the target
gene set by GSEA and GSA are quite similar, especially
when the PCG is high. Consequently, restandardization in
GSA does not seem to be very efficient in this simulation
study, especially when there are many correlated genes.
Third, to show the sensitivity and specificity of Sub-GSE,
we need a group of gene sets that are related with the phe-
notype. Therefore, we do another set of simulations simi-
lar as simulation 1. The detailed descriptions of the
simulation and the resulting ROC curves can be found in
the supplementary materials [see Additional file 1]. The
results show that the higher the PCG and the correlation
coefficient are, the higher the AUC score is. Once the cor-
relation coefficient is higher than 0.4, the AUC score is
higher than 0.85 no matter what the PCG is. When PCG
is higher than 0.5, the AUC score can be higher than 0.75
regardless of the correlation coefficient.
Simulation 2
In reality, most phenotypes are the joint effect of multiple
genes, probably from multiple pathways. Therefore, we
also simulate a more realistic case where the phenotypes
are assumed to be a complex function of expression levels
from two gene sets. As in simulation 1, we again consider
1000 genes divided equally into 50 non-overlapping gene
sets of 20 genes in each. For fixed PCG and ρ,
1. Simulate the expression profiles of the 1000 genes as in
the first simulation for 100 individuals;
2. Choose two gene sets K1 and K2 from the 50 gene sets.
Let  SK1 and  SK2 be the correlated genes in K1 and  K2,
The distribution of p-values under the null hypothesis of no  association Figure 2
The distribution of p-values under the null hypothesis 
of no association. The histogram of the p-values under the 
null hypothesis of no association between the gene sets and 
the phenotype.
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The robustness of Sub-GSE based on simulation 1 Figure 3
The robustness of Sub-GSE based on simulation 1. The standard deviation of the p-values across the 100 runs of Sub-
GSE on simulation 1 is plotted against the average p-values for all the gene sets.
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respectively. Define the phenotype for the j-th individual
as
where j has a normal distribution with mean 0 and vari-
ance 0.25.
3. Analyze the data using GSEA, SigPath, GSA, and Sub-
GSE to rank the gene sets. Rank all the gene sets in increas-
ing order of their q-values.
4. Repeat steps 1–3 100 times to assess the performance of
the different analytic methods by the effects of the differ-
ent gene expression data.
We study the robustness of Sub-GSE as follows. Similar to
the process in simulation 1, for each given correlation
coefficient and PCG, we randomly choose a phenotypic
data and the corresponding gene expression data. Sub-
GSE is applied to the chosen data set for 100 times. The
standard deviation of the p-values across the 100 runs for
all the gene sets is plotted against the average p-values in
Figure 5. Again, the standard deviation of the p-values
across different runs for each gene set is smaller than
0.006. The closer the average p-value is to either 0 or 1, the
smaller the standard deviation is. The maximum standard
deviation is achieved when the average p-value is around
0.5.
For this simulation study, we again apply the four differ-
ent methods to prioritize the gene sets as in the first sim-
ulation study and calculate the average rank of the two
target gene sets. The results can be found in Figure 6.
As shown in Figure 6, the average ranks of the target gene
sets based on all the methods are relatively high. This
could result from the involvement of two different gene
sets when simulating the phenotypic data and the fact that
the phenotypic data are the sum of the squared expression
levels of correlated genes. Another potential complicating
factor is that the phenotype includes a noise in addition
to the function of the gene expression levels of the com-
ponent genes. All these facts can weaken the correlation
between the phenotypic data and the gene expression pro-
file of individual genes inside the true gene sets. Despite
these problems, Sub-GSE performs relatively well com-
ye e ji j
iS K
ij j
iS K
=+ + +
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Comparison results of the different tests based on simulation 1 Figure 4
Comparison results of the different tests based on simulation 1. The average ranks of the gene set related to the phe-
notype for Sub-GSE, GSEA, GSA, and SigPath for different percentages of correlated genes (PCG) and correlation coefficients 
within the chosen genes. The left panel compares the average ranks in 2-D plots in which each subplot corresponds to one 
value of PCG. For a given PCG, the average ranks from the four methods are plotted against the correlation coefficient between 
the correlated genes. The right panel shows the average rank versus the percentage of correlated genes and correlation coeffi-
cient in a 3-D plot.
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The robustness of Sub-GSE based on simulation 2 Figure 5
The robustness of Sub-GSE based on simulation 2. The standard deviation of the p-values across the 100 runs of Sub-
GSE on simulation 2 is plotted against the average p-values for all the gene sets.
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pared to the other three methods, especially when PCG is
low. When PCG is high, the performances of Sub-GSE are
close to those of GSEA and GSA since both GSEA and GSA
consider all the genes inside the gene sets. Again, the per-
formances of GSEA and GSA are similar.
Male Vs. Female Lymphoblastoid Cells
We also apply Sub-GSE to two real data sets from [14]. The
first data set measured the mRNA expression profiles from
lymphoblastoid cells derived from 15 males and 17
females using Affymetrix U133A chip. The gender of the
individuals represents the corresponding phenotypic
data. The gene sets are chosen as the cytogenetic sets (C1,
319 gene sets) and the functional gene sets (C2, 522 gene
sets) defined in [14]. The cytogenetic sets contain 24 gene
sets, one for each of the 24 human chromosomes, and
295 gene sets corresponding to cytogenetic bands along
the chromosomes. The functional sets include 472 gene
sets containing genes whose products are involved in spe-
cific metabolic and signaling pathways, as reported in
eight publicly available, manually curated databases, and
50 gene sets containing genes co-expressed in response to
genetic and chemical perturbations, as reported in various
experimental studies (see supporting text in [14] for
details). We apply Sub-GSE, GSEA, and SigPath to these
two types of gene sets independently with the objective of
identifying the cytogenetic regions that are differentially
expressed between males and females and the functional
gene sets related to sex distinction, respectively.
First, we apply Sub-GSE to investigate the enrichment of
cytogenetic gene sets (C1). As expected, the three most sig-
nificant cytogenetic bands are chrY, chrYp11 and chrYq11
which all have a q-value of 0 and are the only three cytoge-
netic bands from chromosome Y in gene sets C1. They are
also the only three significant gene sets in C1 by GSEA
(FDR < 0.2) and SigPath (max q-value < 0.2). Besides
these expected bands on chromosome Y, other bands that
are ranked as the top 7 among all the gene sets by Sub-
GSE, GSEA and SigPath are listed in Table 1. As seen from
the lists, Sub-GSE is sensitive enough to identify cytoge-
netic bands on both chromosomes X and Y at the q-value
threshold of 0.20. On the contrary, neither GSEA nor Sig-
Path is able to detect any bands on chromosome X at the
FDR threshold of 0.20. Again, this result shows the sensi-
tivity of Sub-GSE.
Comparison results of the different tests based on simulation 2 Figure 6
Comparison results of the different tests based on simulation 2. The average ranks of the target gene sets by Sub-
GSE, GSEA, GSA and SigPath for different percentages of correlated genes and correlation coefficients in Simulation II. The left 
panel compares the average ranks in 2-D plots in which each subplot corresponds to one value of PCG. For a given PCG, the 
average ranks of the target sets from the four methods are plotted against the correlation coefficient between the correlated 
genes. The right panel shows the average ranks of the target sets versus the PCG and correlation coefficient in a 3-D plot. The 
four cubes correspond to Sub-GSE, GSEA, GSA and SigPath.
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Second, we apply Sub-GSE to investigate the enrichment
of functional gene sets (C2). Both Sub-GSE and GSEA
detect three significant gene sets whose significance levels
are listed in Table 2: testis-related genes, genes that escape
X inactivation, and female reproductive tissue-expressed
genes. The q-values of all the other gene sets are larger
than 0.9 by Sub-GSE. Hence, in this dataset, the results by
Sub-GSE are roughly the same as those achieved by GSEA.
P53 Status in Cancer Cell Lines
The second real data set corresponds to the gene expres-
sion data and phenotypic data related to p53 mutation
status from [14]. The objective of this study is to identify
novel targets of the transcription factor p53. The p53
mutation status gene expression data examined the gene
expression patterns from the NCI-60 collection of cancer
cell lines. The expression profiles were measured using
Affymetrix U95Av2 chips. The mutational status of the
p53 gene had been reported for 50 of the NCI-60 cell
lines, with 17 being classified as normal and 33 as carry-
ing mutations in the gene. We take the gene expression
profiles of these 50 cell lines as the expression data and
the vector of binary indicators of the mutational patterns
(normal or mutated) as the corresponding phenotypic
data. For the gene set data, we only use the functional sets
(C2, 522 gene sets) in [14], which was already described
in the application noted above. Functional sets that have
a q-value smaller than or equal to 0.03 by Sub-GSE are
extracted and listed in Table 3 together with their q-values.
Comparing the list of significant gene sets by Sub-GSE and
GSEA [14], we can see that Sub-GSE obtains more signifi-
cant gene sets than GSEA does, which again shows the
sensitivity of Sub-GSE. The relationship between the iden-
tified gene sets by Sub-GSE (Table 3) and p53 is illustrated
in Figure 7. Basically, all these gene sets are significantly
enriched in genes that are differentially expressed in p53
mutants versus those without p53 mutations. Therefore,
the identified gene sets by Sub-GSE are potentially those
regulated by p53. According to the definitions of these
gene sets, as shown in Figure 7, we can roughly divide
them into three groups.
The first group includes gene sets that are directly regu-
lated or affected by p53, including the "p53 signaling
Table 3: Significant functional gene sets related to p53 
mutational status by Sub-GSE.
Set Name q-value
Hypoxia and p53 in the Cardiovascular system <0.001
G1 and S Phases of the Cell Cycle <0.001
p53 Signaling Pathway (p53 Pathway) 0.022
TrkA Signaling Pathway 0.022
P53 Upregulated Genes 0.022
p53 Signaling Pathway Genes(p53_signalling) 0.029
Cell Cycle: G2/M Checkpoint 0.029
G2 and M Phases of the Cell Cycle 0.029
Programmed Cell Death 0.029
DNA Damage Signaling Pathway 0.029
Radiation Sensitivity Genes 0.029
Cell Cycle Regulator Genes 0.029
ATM Signaling Pathway 0.029
Ceramide Signaling Pathway 0.029
Drug Resistance and Metabolism Genes 0.029
Stress Induction of HSP Regulation 0.029
Multi-step Regulation of Transcription by Pitx2 0.029
Fas Signaling Pathway 0.029
Significant functional gene sets (q-value ≤ 0.03) detected in 50 of the 
NCI-60 cell lines. The q-values are calculated by Sub-GSE.
Table 1: Comparison of the top 7 cytogenetic bands related to gender detected by different methods.
Sub-GSE GSEA sigPath
set names q-value set names FDR set names max q-value
chrY 0 chrY 0 chrY 0
chrYq11 0 chrYq11 0.000801147 chrYq11 0
chrYp11 0 chrYp11 0.000811309 chrYp11 0
chrXp22 0.147 chrYp11_Xp22 0.25508726 chrYp11_Xp22 0.315700257
chrX 0.294 chr11p12 0.31999215 chr1q22 0.990782566
chrXp11 0.686 chr6q24 0.6108403 chr20p11 0.991916264
chr15q11 0.924 chr5p14 0.6131663 chr15q21 0.991916264
The top 7 gene sets by Sub-GSE, GSEA and sigPath and their corresponding p-values, FDR and max q-values. The cytogenetic bands chrYp11_Xp22 
was named chrYp22 in the original gene set data which include 8 genes that are on both chrYp11 and chrXp22.
Table 2: Comparison of the significant functional gene sets 
related to gender by Sub-GSE and GSEA.
Set Name Sub-GSE (q-value) GSEA (FDR)
Testis related genes <0.001 0.012
Genes that escape X inactivation 0.165 <0.001
Female reproductive tissue 
expressed genes
0.165 0.045
The top 3 functional gene sets and their corresponding q-values and 
FDR rates by Sub-GSE and GSEA.BMC Bioinformatics 2008, 9:362 http://www.biomedcentral.com/1471-2105/9/362
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pathway", "p53 signaling pathway genes", and "p53
upregulated genes". This group of gene sets was detected
by both Sub-GSE and GSEA [14] (FDR < 0.015).
The second group contains gene sets that are "down-
stream" of p53. These gene sets can either be induced or
inhibited by p53 [35-38]. For example, it is well known
that p53 induces cell cycle arrest during the G1/S phase
and the G2/M phase checkpoint [36]. By itself, p53 can
activate an important death receptor, Fas, which triggers
the "Fas Signaling Pathway" and thus leads to apoptosis
[38]. It is also well known that p53 functions "upstream"
of ceramide in response to genotoxic stress [37].
The third group includes gene sets related to the
"upstream" biological processes or genes for p53. These
"upstream" biological processes, such as DNA damage
caused by radiation or chemical carcinogens, for example,
pass the DNA damage signal down to p53 and further
induce some of the "downstream" pathways. Two genes,
TrkA and Pitx2, are known to affect apoptosis through reg-
ulation of p53 [39,40]. The gene sets related to these
"upstream" biological processes actually include genes
related to those "downstream" biological processes in the
second group.
In this dataset, Sub-GSE not only detects the gene sets
identified by GSEA [14], but also detects more novel gene
sets related to p53. Previous studies from the literature
support the findings in that all the significant gene sets
identified by Sub-GSE are related to p53, as shown in Fig-
ure 7.
Conclusion
To summarize, we have developed a method, called Sub-
GSE, to identify gene sets that are associated with a phe-
notype by testing the association between the strict sub-
sets of genes and the phenotype. In many applications, it
is very likely that only a subset of genes in a gene set of
interest is associated with the phenotype. However, since
currently available methods for gene set enrichment anal-
ysis usually test the association of all the genes in a gene
set with the phenotype, the power of these methods is cor-
respondingly reduced. In contrast, Sub-GSE is based on
the idea of set-association approach first proposed by [32]
and it incrementally tests the association of "strict sub-
sets" with the phenotype. The strict subsets contain the
Relationship between the significant gene sets and p53 Figure 7
Relationship between the significant gene sets and p53. Relationship between significant gene sets and p53. Solid 
arrows describe the interactions between p53 and different biological processes or genes. Dashed arrows show the definition 
of those gene sets in the corresponding dashed rectangle. The solid arrows are constructed based on previous works in [35-
40].
P53
DNA Damage
Hypoxia
Radiation
Heat Shock
Chemical Carcinogens
DNA Damage Signaling Pathway
Hypoxia and p53 in Cardiovascular System
Radiation Sensitivity Genes
ATM Signaling Pathway
Stress Induction of HSP Regulation
Drug Resistance and Metabolism Genes
p53 signaling pathway
p53 signaling pathway genes
p53 upregulated genes
Cell Cycle Arrest Apoptosis
G1 and S Phase of Cell Cycle
Cell Cycle:G2/M Checkpoint
G2 and M Phases of Cell Cycle
Cell Cycle Regulator Genes
Programmed Cell Death
TrkA
Pitx2
TrkA Signaling Pathway
Multi-step Regulation of Transcription by Pitx2
Ceramide
Fas
Ceramide Signaling Pathway
Fas Signaling PathwayBMC Bioinformatics 2008, 9:362 http://www.biomedcentral.com/1471-2105/9/362
Page 12 of 15
(page number not for citation purposes)
genes having the top association strength of individual
genes with the phenotype. We first study the performance
of Sub-GSE and compare it with three widely used meth-
ods for gene set enrichment analysis: GSEA, GSA, and Sig-
Path. Our simulations show that Sub-GSE outperforms
GSEA, GSA, and SigPath in prioritizing gene sets associ-
ated with a phenotype when the fraction of genes associ-
ated with the phenotype is relatively small. On the other
hand, these four methods all achieve similar results when
the fraction of associated genes is large. When applied to
two real data sets, Sub-GSE is shown to detect more bio-
logically meaningful gene sets than GSEA. For example,
Sub-GSE identified cytogenetic band Xp22 as significantly
associated with gender (q-value < 0.20), while neither
GSEA nor SigPath identified them as significant at a FDR
< 0.20. Similarly, Sub-GSE identified many gene sets
including, for instance, DNA damage genes, cell cycle
checkpoints genes and programmed cell death genes, as
significantly associated with p53 mutation status. These
were not identified by GSEA. This evidence supports the
high sensitivity of Sub-GSE. Most of the detected gene sets
have supports from previous studies for the association
between them and the p53 mutations.
Usually a large number of sets will be detected as signifi-
cant for most tests of gene enrichment analysis. Since Sub-
GSE is more sensitive in detecting significant gene sets
than other tests for gene set enrichment analysis, we
expect that many more gene sets will be identified as sig-
nificant. This may reflect biological reality instead of sta-
tistical artifacts. For example, cancer can affect a large
number of genes and gene categories. By studying the GO
relationship among the significant gene sets, the more
specific significant GO categories may represent the real
underlying affected function categories.
The advantages of Sub-GSE over other approaches for test-
ing gene set enrichment are most evident when only a
fraction of the genes in the gene set of interest are associ-
ated with the phenotype. If we believe that most genes in
a gene set of interest are associated with the phenotype,
other approaches, including GSEA, GSA, and SigPath,
may perform better than Sub-GSE. Under this scenario,
the use of the minimum p-value across all the strict sub-
sets as a test statistic, which is done in Sub-GSE, would
result in the introduction of more noise. It is possible that
the minimal p-value may be achieved for some subsets of
the gene set of interest, making Sub-GSE less powerful.
The results of our simulations are consistent with this
observation. On the other hand, our simulations also
showed that the performance of Sub-GSE is only margin-
ally worse than the other approaches under the conditions
noted above. We do not claim that Sub-GSE is always bet-
ter than GSEA, GSA, or SigPath. Instead, Sub-GSE comple-
ments other approaches for gene set enrichment analysis
when the fraction of associated genes is relatively small.
The speed of Sub-GSE is determined by the number of
gene sets and the number of genes inside each gene set. To
give an example of the running time, we download the
gene expression data with accession number GSE5081
from NCBI http://www.ncbi.nlm.nih.gov/ which hybrid-
ized total RNAs from gastric biopsy specimens of patients
with Helicobacter pylori positive (HP+) and Helicobacter
pylori negative (HP-) antrum erosions (ER+), and the cor-
responding, adjacent normal mucosae (ER-). The gene
expression data includes 54675 probes and 32 samples.
HP+ and HP- are treated as the phenotype. Mappings
between the probes and GO categories are from the R
package http://www.r-project.org/ named
"hgu133plus2". All the probes are mapped to 8310 GO
categories in total. We run Sub-GSE on this data set using
a computer with Pentium 4 CPU 3.60 GHz/3.59 GHz,
1.00 GB of RAM. It took 12.7 hours when 1000 permuta-
tions are required and the strict set size threshold is 1.
Usually we need to simultaneously test the association of
a large number of gene sets with the phenotype. For each
gene set, we can use Sub-GSE to test the association of the
gene set with the phenotype to obtain a p-value. We have
shown in the "Results" section that the p-value is uni-
formly distributed under the null hypothesis that no sub-
set is associated with the phenotype. When we test for a
large number of gene sets, the issue of multiple testing is
of concern. To solve this problem, conventional methods
such as Bonferroni correction can be used. However, Bon-
ferroni correction is too conservative in most situations.
Another currently widely used method dealing with mul-
tiple testing is to control false discovery rate (FDR) as
implemented in the software package QVALUE [34]. For
the QVALUE package to work well, the p-values for all the
gene sets need to be weakly dependent. When the sizes of
the gene sets are relatively small compared to the total
number of genes, we expect that the p-values to be weakly
dependent since the genes usually form modules and
genes from different modules are more likely to be inde-
pendent. When these assumptions are in doubt, we can
use the p-values obtained from Sub-GSE to indicate the
statistical significance of the gene sets.
There are two options in Sub-GSE: the minimal size for
the strict sets and the statistic to measure the association
strength between gene expression profiles and the pheno-
type. We set the tuning parameter c to be the minimal size
of the strict subsets on which to test. Parameter c can con-
trol the sensitivity and the specificity of Sub-GSE, thus
having a significant effect on its performance. Generally,
the sensitivity of Sub-GSE decreases and the specificity
increases as c increases. Therefore, the choice of c shouldBMC Bioinformatics 2008, 9:362 http://www.biomedcentral.com/1471-2105/9/362
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depend on the balance between sensitivity and specificity.
Although we set c = 5 in this paper, which restricts the
minimal size for the strict sets, we can, instead, require
that the minimal size of the strict sets depend on the size
of the gene set of interest. For example, one could con-
sider the subsets of genes that cover at least 10% of the
given genes inside each gene set. Since the minimal set
size of the subset may be different for different gene sets,
the effects of this type of restriction need to be further
studied. The other Sub-GSE option involves the statistic
used to measure the association strength between gene
expression profiles and the phenotype. In this paper, we
use t-statistics, Kruskal-Wallis statistics, and Pearson's cor-
relation to evaluate the association strength between the
gene expression profiles and discrete, categorical, and
quantitative phenotypes, respectively. Other statistics can
also be applied. The power of Sub-GSE to detect enriched
gene sets for different types of statistics also needs to be
further studied.
It is well known that genes in the same pathway or com-
plex tend to be correlated. A natural question is whether it
is better first to do principal component analysis (PCA)
and then apply Sub-GSE to the principal components. We
implemented this idea and found the approach less pow-
erful than the method implemented in this paper. A
potential explanation is that the expression profiles of the
genes in the gene sets among the cases and controls do not
satisfy the normality assumption making the PCA
approach less powerful. More studies are needed to see
under what conditions the combination of PCA and Sub-
GSE is more powerful than Sub-GSE alone.
Methods
Association strength measures for individual genes
For a given gene, suppose the gene expression levels meas-
ured in the experiment are (e1, e2, , em), where m is the
number of samples. The corresponding phenotypic data
for the m  samples are denoted as C  = (c1,  c2,,  cm).
Depending on the measurement levels of C, we measure
the association strength between the gene expression and
phenotype by the absolute value of t-statistic, Kruskal-
Wallis statistic or Pearson correlation coefficient for
binary, discrete or continuous phenotypic data, respec-
tively.
Local association statistic for each strict subset and the 
global statistic for the gene set
Suppose the given gene set has a total of s genes and the
sorted association strength measures are a1 ≥ a2 ≥  ≥ as.
According to the definition of the strict subsets, the i-th
strict subset include genes that correspond to (a1, a2,, ai).
The local association statistic for the strict subset i  is
defined as
We use the permutation test described below to define a
p-value, pi for the i-th strict set. The statistic for the given
gene set is the minimum p-value over all the strict sets, i.e.
Permutation test
We employ the algorithm in [41] to assess the significance
of the given gene set. The algorithm permutes the pheno-
typic data C = (c1, c2,, cm) for N times and keep the gene
expression data intact. After each permutation, the associ-
ation strength measures are re-calculated using the per-
muted phenotypic data and the "strict subsets" are re-
defined. Suppose that the statistics   for the n-th per-
mutation and the i-th strict subset are organized as
where c is the minimum number of genes in the strict sets.
Here we take the observed data as the permutation 0.
Based on the data matrix, we calculate the raw p-value for
the i-th strict set of the observed data as
The testing statistic for the gene set is
.
To estimate the distribution of Pmin under the null hypoth-
esis, we replace the observed "strict subset" statistics with
the permuted ones. The permuted raw p-values for the n-
th permutation and i-th strict subset are calculated by
The minimum p-value   is taken as one
of the random sample from the distribution of Pmin under
the null hypothesis. Finally the significance of the gene set
is calculated as
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Multiple testing correction for multiple gene sets
In a typical situation, there will be multiple gene sets to be
analyzed. After we assess the significance level for each of
them according to the procedure described above, q-val-
ues of all the given gene sets are calculated using the
QVALUE R package [34] for multiple testing correction.
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